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Ile105ValAbstract Background: Endometrial hyperplasia (EH) occurs when the endometrium, the lining of
the uterus, becomes too thick, causing abnormal uterine bleeding. In some cases, it can lead to
endometrial carcinoma if untreated. Glutathione-S-transferases (GSTs) enzymes have a role in
the metabolism of a lot of disease-causing carcinogens and mutagens that are present in environ-
ments of human. GSTP1–313 A> G gene polymorphism was associated with signiﬁcantly high risk
of endometrial carcinoma in some reports. The aim of this work is to assess the association of this
polymorphism with the susceptibility of EH among a sample of Egyptian women.
Subjects and methods: This study included 84 unrelated EH Egyptian women who were
compared to 134 healthy controls from the same locality. For all subjects, DNA was genotyped
for GSTP1–313 A> G (Ile105Val) polymorphism using the PCR–RFLP technique.
Results: The frequency of GSTP1–313 AG and GG genotypes was noted to be signiﬁcantly
higher among most of the cases with EH compared to controls (79.8% vs. 42.0%, OR= 8.63,
95% CI = 4.53–16.46, p< 0.001). Also the frequency of the GSTP1–313 G allele was signiﬁcantly
higher among most of the cases compared to controls (24.9% vs. 16.8%, OR= 3.72, 95%
CI = 2.39–5.79, p< 0.001). Furthermore, there was a signiﬁcant increase of endometrial thickness
in the EH women compared to controls (p< 0.001).
Conclusions: GSTP1–313 G allele carriage was associated with susceptibility of EH among a
sample of Egyptian women.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Ain Shams University. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)..
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Endometrial hyperplasia (EH) is deﬁned as an excessive prolif-
eration of the cells of endometrium. It does not represent a
health risk to women, however, it is a precursor lesion of most
endometrial carcinoma. It is always detected following the
investigation of women with symptoms of abnormal uterine
bleeding [1,2]. EH has been classiﬁed into 3 main types: (1)
simple hyperplasia that is characterized by less amount of
endometrial glandular crowding with low risk of hyperplasia
progress to carcinoma; (2) complex hyperplasia that is charac-
terized by major amount of endometrial glandular crowding
with medium risk of progression; and (3) atypical hyperplasia
that is comprised of endometrium with complex glandular
crowding and the risk of endometrial carcinoma progression
is greatest [3,4].
The endometrium, a target tissue of sex-steroid hormones,
consists of two main structural components, the specialized
endometrial stroma and the endometrial glands [5].
Endometrial hyperplasia typically occurs when unopposed
estrogen (i.e., in the absence of progesterone) stimulates
abnormal proliferation of endometrial glands. Estrogen drives
endometrial proliferation during the menstrual cycle, and
chronic excess estrogen activity is a well established risk factor
for endometrial hyperplasia [5,6]. The etiology of endometrial
hyperplasia is unclear, although a multifactorial origin from a
combination of immunologic, genetic and environmental
factors are considered to be the most plausible [5–7]. Recently,
multiple lines of evidence from genetic origin suggest that EH
has a substantial hereditary component [8–10]. Moreover, there
is an increased risk of EHby conditions accompaniedwith inter-
mittent or the absence of ovulation.Aftermenopausewhen ovu-
lation has ceased, EH is very common in women who have
conditions that cause the levels of circulating estrogen to
increase such as in estrogen replacement therapy or obesity
[6,7]. Decreased progesterone activity is a risk factor for
endometrial hyperplasia. Obesity contributes to decreased pro-
gesterone activity due to obesity-associated anovulation [7].
Glutathione-S-transferases (GSTs) are key enzymes of
phase II related to the metabolism of numerous genotoxic
compounds. Glutathione-S-transferases M1 (GSTM1) and
T1 (GSTT1), the important subtypes of GSTs enzymes, are
reportedly involved in detoxiﬁcation of estrogen and reactive
oxygen species, which are considered to play a key role in
the occurrence of various endocrine-related cancers [11,12].
Another member of the glutathione-S-transferase (GST)
family, GSTP1, which is located at 11q13, has a role in the
detoxiﬁcation of electrophilic compounds by glutathione
conjugation [11]. It has been found that two genetic polymor-
phisms in exon 5 and exon 6, lead to amino acid substitutions.
However, only the transition in exon 5 was linked to activity of
enzymes since this is located within the region coding for the
enzyme’s active site. The genetic change in exon 5 at the site
-313, results in polymorphism at codon 105, where an
adenosine-to-guanidine (A> G) transition causes an Ile-
to-Val substitution [13]. Furthermore, many studies reported
that GSTP1 has a role in biotransformation of many pollu-
tants of environment [14]. This suggests that GSTP1 may be
the most important GST in the pathogenesis of endometrial
hyperplasia. For this reason, several studies have been con-
ducted to evaluate the association of GSTP1–313 A> Gpolymorphism with endometrial carcinoma risk [15–22], but
there were no previous results evaluating the association
between this polymorphism and endometrial hyperplasia.
Therefore, the aim of our study is to derive a more precise
estimation of the association between GSTP1–313 A> G
(Ile105Val) polymorphism and EH susceptibility among
Egyptian women.2. Subjects and methods
This work is a case controlled study involving 84 women rep-
resented by a history of simple endometrial hyperplasia (SEH)
[3,4] with an age mean ± SD of 48.2 ± 3.1 years, in addition
to a control sample of 134 healthy unrelated women with an
age mean ± SD of 47.2 ± 3.3 years. They were recruited from
the outpatient clinic of Obstetrics and Gynecology
Department, Faculty of Medicine, Mansoura University,
Egypt. All the patients were asked to complete a questionnaire
regarding general characteristics including age, age at menar-
che, gravidity and parity. Body mass index (BMI) was calcu-
lated as weights (kg) divided by the heights (m2). Exclusion
criteria included women who were documented to have uterine
ﬁbroid, endometrial carcinoma, cancer ovary, cancer colon, as
well as those who received any hormonal therapy during the
last 3 months prior to the study.
For all participants, genomic DNA from a peripheral blood
was extracted and puriﬁed (Gentra Systems, USA).
Genotyping of the GSTP1 Ile105Val gene polymorphism
at exon 5 was carried out via the polymerase chain reaction-
restriction fragment length polymorphism method (PCR-
RFLP), using the forward (50-ACC CCA GGG CTC TAT
GGG AA-30) and reverse (50-TGA GGG CAC AAG AAG
CCC CT-30) primers, which were used to generate a segment
of 176 bps of the GSTP1 gene [23]. The PCR ampliﬁcation
was carried out using Veriti Thermal Cycler (Applied
Biosystems) in a volume containing about 50 ng genomic
DNA template, 200 lM of each dNTP, 200 ng of each primer,
1.5 mM MgCl2, 1· PCR buffer (50 mM KCl, 10 mM
Tris–HCl, pH 8.3), and 1 U Taq DNA polymerase. This
ampliﬁcation was carried out with an initial denaturation step
at 95 C for 10 min, this step was followed by 30 cycles at
94 C for 30 s, 55 C for 30 s and 72 C for 30 s and a ﬁnal
extension at 72 C for 10 min. The ampliﬁed products were
digested for 2 h at 37 C with 2 U Alw26I (Thermo Fisher
Scientiﬁc, Catalog number: FD0034). The product of digestion
was applied on a 2% agarose gel that was stained with
ethidium bromide. Electrophoresis of the digested PCR
products showed individuals homozygous (ile/ile) for the
GSTP1 ile105val polymorphism as one band of 176 bp.
Heterozygous (ile/val) for the polymorphism showed three
bands of 176, 91 and 85. Homozygotes (val/val) showed two
bands of 91 and 85 bp.
2.1. Ethical approval and informed consent
This study was started after getting an approval from the
university scientiﬁc and ethics committees. In addition, an
informed consent was obtained from all participants before
their enrollment into the study. The work has been carried
out in accordance with the code of ethics of the world medical
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humans results.
2.2. Statistical analysis
Data were analyzed and processed using the Statistical
Package of Social Science (SPSS, version 17.0). The frequen-
cies of studied allelic and genotypic variants among cases were
compared to the controls using Fisher’s exact test and odds
ratio (OR) with the 95% conﬁdence interval (95% CI).
Quantitative traits were compared using the Student t-test
while nominal traits were compared using the Chi square
test. Conformity with the Hardy Weinberg law of genetic
equilibrium (HWE) was tested comparing the observed versus
the expected genotype frequencies in control and cases. A
minimum level of statistical signiﬁcance was obtained at a p
level of <0.05.
3. Results
The clinical and demographic data of the EH women are
shown in Table 1. It was noted that there was no signiﬁcantTable 1 The main demographic and clinical characteristics of
patients of endometrial hyperplasia compared to controls.
Variable* Cases
n= 84
Controls
n= 134
p
Age, years, M± SD 48.2 ± 3.1 47.2 ± 3.3 0.35
Age at menarche, years,
M± SD
12.8 ± 6.2 13.6 ± 4.8 0.76
Gravidity, M± SD 6.2 ± 1.6 5.8 ± 2.2 0.32
Parity, M± SD 4.4 ± 1.2 3.9 ± 0.85 0.53
BMI, (kg/m2) 28.9 ± 2.3 27.6 ± 1.8 0.82
Endometrial thickness
(ET), mm
15.8 ± 1.9 12.2 ± 1.4 <0.001**
* BMI, Body mass index.
** p< 0.001 = highly signiﬁcant.
Table 2 The genotype and allele frequencies of GSTP1–313 A> G
EH patients
n (%) 84
Genotypes
AA (ile/ile) 17 (20.2)
AG (ile/val) 62 (73.8)
GG (val/val) 5 (6.0)
Alleles
A (ile) 96 (57.1)
G (val) 72 (24.9)
HWE v2 = 21.6, p< 0
Statistics
Recessive GG vs. AA+ AG
Dominant AG+GG vs. AA
Heterozygote model AG vs. AA
Overdominant AG vs. AA +GG
Allele G vs. A
OR, odds ratio; CI, conﬁdence intervals; HWE, Hardy–Weinberg equil
** p< 0.001 = highly signiﬁcant.difference of age, age at menarche, gravidity, parity and
BMI between EH women and controls. However, there was
a signiﬁcant increase of endometrial thickness in the EH
women compared with controls (p< 0.001). The genotypic
and allelic frequencies of the GST91–313 A> G gene SNP
in EH women and controls are shown in Table 2. Hardy–
Weinberg equilibrium (HWE) relied no signiﬁcant difference
(p= 0.63) between the observed and frequencies that were
expected of GSTP1–313 A> G genotypes of the controls that
may be supporting the selection of controls. However, HWE
showed a signiﬁcant deviation of the observed frequencies of
cases from the expected ones (p< 0.001), probably due to
the high frequency of heterozygote on the expense of homozy-
gote genotypes. This is attributed to the small sample size
rather than the existence of heterozygote advantage or hetero-
sis (Table 2).
Testing for the dominant model of inheritance (AG+ GG
vs. AA) showed that cases had a signiﬁcantly higher frequency
of AG+ GG genotypes compared to controls (79.8% vs.
42.0%, OR = 8.63, 95% CI = 4.53–16.46, P< 0.001).
Testing for Heterozygote model (AG vs. AA), cases showed a
signiﬁcantly higher frequency of AG genotype compared to
controls (73.8% vs. 29.1%, OR = 8.60, 95% CI = 4.47–
16.55, P< 0.001). Testing for the recessive model (GG vs.
AA+ AG), cases showed no signiﬁcant difference of the GG
homozygous genotype compared to the controls (6.0% vs.
2.3%, OR = 2.76, 95% CI = 0.64–11.88, p= 0.26).
Regarding the allelic frequencies, cases showed a signiﬁcantly
higher frequency of the GST91–313 G allele compared to con-
trols (24.9% vs. 16.8%, OR= 3.72; 95% CI = 2.39–5.79,
P< 0.001) (Table 2).
4. Discussion
Several hormonal, immunologic and environmental factors
have a role in the endometrial hyperplasia development [9].
The GST gene is one of the important genes which has a role
in regulate immune, metabolism, endocrine and are closelyin the EH patients and control groups.
Controls
n (%) 134
92 (68.6)
39 (29.1)
3 (2.3)
223 (83.2)
45 (16.8)
.001** v2 = 0.23, p= 0.63
OR (95% CI) p
2.76 (0.64–11.88) 0.26
8.63 (4.53–16.46) <0.001**
8.60 (4.47–16.55) <0.001**
6.86 (3.72–12.67) <0.001**
3.72 (2.39–5.79) <0.001**
ibrium.
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GSTP1 is the most important member of GST family which
contributes to the detoxiﬁcation of electrophilic compounds
by glutathione conjugation [11]. Furthermore, GSTP1 is a
key substance in the biotransformation and inactivation of cer-
tain environmental pollutant. Due to enzymatic activity of
GSTP1–313 A> G polymorphism, GSTP1 may confer sus-
ceptibility to several cancers [23,25].
Multiple studies have been focused on GSTP1–313 A> G
polymorphism and the risk of various cancers, including lung,
breast, colorectal, bladder, pancreatic, thyroid and prostate
cancer [25]. Some reports showed that GSTP1–313 A> G
polymorphism was associated with the risk of prostate, blad-
der and gastric cancer [26–28]. On the contrast, this polymor-
phism was not associated with susceptibility to colorectal
cancer, hepatocellular carcinoma or breast cancer [29–31].
Knowing these facts, this study was planned to investigate
the association between GSTP1–313 A> G polymorphism
and endometrial hyperplasia. To our knowledge, this is the
ﬁrst report of a probable association between this polymor-
phism and Egyptian EH women.
High GSTP1–313 G allele carriage (AG+ GG genotypes)
was signiﬁcantly noted among Egyptian women with EH cop-
ing with the dominant model of inheritance.
Several studies have been performed to assess the associa-
tion of GSTP1–313 A> G polymorphism with endometriosis
risk, but the results remain inconclusive. One study done
among Turkish women, found that GSTP1–313 A> G poly-
morphism might contribute to the risk of endometriosis with
signiﬁcantly decreased risk for GSTP1 val/val and increased
risk for GSTP1 ile/ile [21]. Nonetheless, several other studies
have found contradictory results in the form of no association
between GSTP1–313 A> G and endometriosis risk in some
other populations like that done among Chinese [15],
Japanese [16], Italian [17], Indian [20] and Korean [22] sub-
jects. A recent meta-analysis study showed that GSTP1–313
A> G polymorphism was not associated with endometriosis
risk in the overall population (A vs. G: OR = 1.02,
P= 0.511) [24]. These contradictory results might be attribu-
ted to different ethnic origins, environmental difference in
addition to problems related to research methodologies like
the adequacy of sample size and proper diagnostic methods.
Therefore, authors do document some limitations of the study
in the form of its relatively small sample size in addition to the
lack of data concerning the GSTP1 gene expression in studied
cases. In this respect, we recommend undertaking a wider scale
study of a large sample size including different disease pheno-
types; investigating their genetic GSTP1 polymorphisms along
with its expression state in the blood and at the site of
inﬂammation.
In conclusion, our data support the association of the
GSTP1 G allele with susceptibility of EH among Egyptian
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